key: cord-1022566-7s9qm7t7
authors: Vergara, Ander; Jacobs-Cachá, Conxita; Molina-Van den Bosch, Mireia; Domínguez-Báez, Pamela; Benito, Begoña; García-Carro, Clara; Serón, Daniel; Soler, María José
title: EFFECT OF RAMIPRIL ON KIDNEY, LUNG AND HEART ACE2 IN A DIABETIC MICE MODEL.
date: 2021-03-31
journal: Mol Cell Endocrinol
DOI: 10.1016/j.mce.2021.111263
sha: 186abcf0eceb71c87e7ca6a5e44c4cd16f9da524
doc_id: 1022566
cord_uid: 7s9qm7t7

BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the current coronavirus disease 2019 (COVID-19). The main organ affected in this infection is the lung and the virus uses the angiotensin-converting enzyme 2 (ACE2) as a receptor to enter the target cells. In this context, a controversy raised regarding the use of renin-angiotensin system (RAAS) blockers, as these drugs might increase ACE2 expression in some tissues and potentially increase the risk for SARS-CoV-2 infection. This is specially concerning in diabetic patients as diabetes is a risk factor for COVID-19. METHODS: 12-week old diabetic mice (db/db) were treated with ramipril, or vehicle control for 8 weeks. Non-diabetic db/m mice were included as controls. ACE2 expression and activity were studied in lung, kidney and heart of these animals. RESULTS: Kidney ACE2 activity was increased in the db/db mice as compared to the db/m (143.2% ± 23 vs 100% ± 22.3% %, p=0.004), whereas ramipril had no significant effect. In the lung, no differences were found in ACE2 when comparing db/db mice to db/m and Ramipril also had no significant effect. In the heart, diabetes decreased ACE2 activity (83% ± 16.8%, vs 100% ± 23.1% p=0.02), and ramipril increased ACE2 significantly (83% ± 16.8% vs 98.2% ± 15%, p=0.04). CONCLUSIONS: In a mouse model of type 2 diabetes, ramipril had no significant effect on ACE2 activity in either kidneys or in the lungs. Therefore, it is unlikely that RAAS blockers or at least angiotensin-converting enzyme inhibitors increase the risk of SARS-CoV-2 infection through increasing ACE2.

In tro d u c tio n T he pa nde m ic ca use d by se ve re a cute re spira tory syndrom e corona virus 2 (S AR S -C oV -2 ) tha t be ga n in D e ce m be r 2 0 1 9 in W uha n, C hina , ha s le d to a worldwide sa nita ry crisis. T he lung is the m a in a ffe cte d orga n in corona virus dise a se -1 9 (C O V ID -1 9 ). S AR S -C oV -2 use s the tra nsm e m bra ne prote in a ngiote nsin-conve rting e nz ym e 2 (AC E 2 ) a s one of the re ce ptors to e nte r the ta rge t ce lls (H offm a nn e t a l., 2 0 2 0 ), a fe a ture sha re d with S AR S -C oV (the virus tha t ca use d the S AR S e pide m ic in 2 0 0 2 ) (Li e t a l., 2 0 0 3 ). AC E 2 is a ca rboxype ptida se tha t tra nsform s a ngiote nsin-I (Ang-I) a nd a ngiote nsin-II (Ang-II) into a ngiote nsin-1 -9 (Ang-1 -9 ) a nd a ngiote nsin-1 -7 (Ang-1 -7 ), re spe ctive ly. T his e nzym e is pa rt of the a lte rna tive pa thwa y of the re nin-a ngiote nsin-a ldoste rone syste m (R AAS ). Its a ctiva tion ha s va sodila tor e ffe cts pe r se a nd re gula te s in a ne ga tive wa y the cla ssica l a rm of the R AAS (va soconstrictor)(O b u k h o v e t a l., 2 0 2 0 ; R o m e ro e t a l., 2 0 1 5 ). AC E 2 is wide ly e xpre sse d in the proxim a l tubula r ce lls of the kidne y (Le ly e t a l., 2 0 0 4 ). In a le sse r e xte nt it is a lso e xpre sse d in the lung (in pne um ocyte s type 2 ) (H a m m in g e t a l., 2 0 0 4 ; S e rfo zo e t a l., 2 0 2 0 ) a nd the he a rt (in ca rdiom yocyte s) (O udit e t a l., 2 0 0 9 ).

T he insights provide d by the first S AR S -C oV pa nde m ic in 2 0 0 2 , re ve a le d tha t S AR S -C oV infe ction induce d a de cre a se in AC E 2 e xpre ssion in the lung. In a cute lung injury, AC E 2 de ficie ncy ha s be e n re la te d with e nha nce d tissue da m a ge , which m a y be a scribe d to a n ove ra ctiva tion of the va soconstrictor a rm of the R AAS (AC E /Ang-II/Angiote nsin-II type 1 re ce ptor a xis) (Kuba e t a l., 2 0 0 6 ). T he re fore , the R AAS se e m s to pla y a n im porta nt role in the se ve rity of lung injury re la te d to S AR S -C oV -2 infe ction. F urthe r, de re gula tion of the R AAS is cla ssica lly se e n in dia be te s a nd cha nge s in AC E 2 e xpre ssion ha ve be e n ide ntifie d in the kidne y a nd the he a rt of dia be tic pa tie nts(R e ich e t D uring the first wa ve of the C O V ID -1 9 pa nde m ic a controve rsy ra ise d re ga rding the use of R AAS blocke rs a s som e studie s in e xpe rim e nta l m ode ls ha ve shown tha t the tre a tm e nt with this drugs incre a se d AC E 2 e xpre ssion in ca rdia c tissue (F e rra rio e t a l., 2 0 0 5 ; Is h iya m a e t a l., 2 0 0 4 ; O c a ra n za e t a l., 2 0 0 6 ) a nd in the re na l va scula ture (S ole r e t a l., 2 0 0 9 ). D ue to this pre clinica l e vide nce it ha s be e n sugge ste d tha t the tre a tm e nt with R AAS blocke rs could incre a se the susce ptibility to S AR S -C oV -2 infe ction cre a ting a pa ra dox a s incre a se d AC E 2 le ve ls a re norm a lly conside re d tissue -prote ctive (Ale ksova e t a l., 2 0 2 0 ; S p a rk s e t a l., 2 0 2 0 ; W a n g e t a l., 2 0 2 0 ). D e spite the re sults of the a fore m e ntione d studie s (F e rra rio e t a l., 2 0 0 5 ; Is h iya m a e t a l., 2 0 0 4 ; O c a ra n za e t a l., 2 0 0 6 ; S ole r e t a l., 2 0 0 9 ) the re is not e nough e vide nce to a ffirm tha t the se drugs prom ote AC E 2 e xpre ssion a s othe r a uthors using sim ila r e xpe rim e nta l m ode ls ha ve not obse rve d AC E 2 m odula tion induce d by R AAS blocke rs (B u rc h ill e t a l., 2 0 1 2 ; B u rre ll e t a l., 2 0 0 5 ).

F urthe rm ore , the e ffe cts of R AAS blocke rs upon lung AC E 2 m odula tion ha ve be e n sca rce ly e va lua te d. In a re ce nt re port, W ysocki a nd colla bora tors de scribe d AC E 2 m odula tion in kidne y a nd lung of m ice (C 5 7 BLKS /J) tre a te d with R AAS blocke rs (te lm isa ta n or ca ptopril) (W ysocki e t a l., 2 0 2 0 ). H e re we study the e ffe cts of a n AC E i (ra m ipril) on kidne y, lung a nd he a rt AC E 2 in a m ouse m ode l of type 2 dia be te s.

Anima l proce dure s E ight-we e k-old m a le le ptin re ce ptor de ficie nt dia be tic m ice (db/db) a nd the nondia be tic he te rozygote litte rm a te s (db/+ ) we re purcha se d from C ha rle s R ive r (BKS .C g-D ock7 m + /+ Le pr db J. S tra in C ode : 6 0 7 ). T he m ice we re house d in groups of 4 pe r ca ge a s m a xim um with a d libitum a cce ss to re gula r m ice C how a nd wa te r unde r a 1 2 h light:1 2 h da rk cycle . Afte r 4 we e ks (1 2 -we e k-old m ice ) a group of db/db (n= 7 ) we re tre a te d with ra m ipril (8 m g/kg/da y) dilute d in drinking wa te r (2 0 m g/L) during 8 we e ks. Ve hicle db/db (n= 7 ) a nd db/m (n= 7 ) we re use d a s controls. W e ight a nd blood glucose we re m onitore d biwe e kly a nd blood pre ssure be fore a nd a fte r the tre a tm e nt (se e supple m e nta l m e thods).

Afte r the tre a tm e nt pe riod, the a nim a ls we re sa crifice d unde r sodium pe ntoba rbita l a ne sthe sia . M ice we re the n pe rfuse d with cold P BS 1 x a nd whole blood wa s obta ine d by respectively) and heart (C and F, respectively) of the db/m, db/db and db/db treated with ramipril mice. ACE2 mRNA significantly increased in the kidney (A) and decreased in the heart (B) of the db/db when compared to the db/m. Ramipril treatment restored ACE2 mRNA in the kidney (A) and had no effect on ACE2 gene expression in the lung and in the heart (panels B and C, respectively). Ramipril treatment did not affect ACE2 activity in the kidney and in the lung of the db/db (panel D and E, respectively). In the heart (F), ACE2 activity was significantly decreased in the db/db (vs db/m) and ramipril normalized ACE2 activity. The data are represented as mean ± SD (n=7) and significance is considered when p ≤ 0.05. The ACE2 activity obtained in kidney (A), lung (B) and heart (C) expressed in RFU/mg/h is shown in supplemental Figure S1 . 1 E , F ig u re 2 B , a n d S u p p le m e n ta l F ig u re 1 a n d 2 , re s p e c tive ly). F u rth e rm o re , in th e lu n g o f th e d b /d b , ra m ip ril tre a tm e n t d id n o t in d u ce ch a n g e s in A C E 2 g e n e e xp re s s io n a n d a c tivity (F ig u re 1 B a n d E , F ig u re 2 B a n d S u p p le m e n ta l F ig u re 1 a n d 2 ). 

com pa re d to the db/m (9 9 .9 % ± 2 9 .3 % vs 1 4 6 % ± 5 7 .2 % , p= 0 .0 3 ) a nd ra m ipril did not m itiga te this e ffe ct (1 4 6 % ± 5 7 .2 % vs 1 2 8 % ± 5 5 .7 % , p= 0 .5 ) (F igure 4 ). Thus, at least for the kidney, our results do not sustain the idea that the RAAS blockade would favor ACE2 overexpression. In human, two independent studies described that tubular ACE2 gene and protein expression were decreased in diabetic nephropathy as compared to healthy individuals (Mizuiri et al., 2008; Reich et al., 2008) , although another author was not able to find any differences . Regarding the effect of RAAS blockade in human, there is some evidence that it affects ACE2 expression in the kidney Reich et al., 2008) .

We also analyzed ACE2 in lung and heart tissues where ACE2 presence is much lower than in the kidney (Supplemental Figure S1 and S2). Regarding the lung, we obtained high interindividual variability in ACE2 gene expression (Figure 1 ) that might be in part explained by the fact that ACE2 expression in the lung is very low and restricted to pneumocytes type 2 (Ziegler et al., 2020) . We obtained sound results when ACE2 was estimated by enzyme activity measurement. Lung ACE2 activity was similar between the control db/m and the diabetic db/db and no differences were seen in the db/db treated with ramipril as compared to the vehicle db/db ( Figure 1E and Figure 2B ). Although ACE2 in lung has not been widely studied in animal models, it has been reported that the NOD Wysocki et al., 2020) . In human, a study in 1051 patients revealed that lung ACE2 gene expression was downregulated by long-term ACEi treatment whereas it was not altered by ARBs (Milne et al., 2020) , although no data regarding ACE2 protein levels or activity were available.

Cardiac ACE2 gene expression and activity was significantly decreased in the db/db mice when compared to the db/m ( Figure 1C and F, respectively). In this case, the treatment with ramipril increased ACE2 activity ( Figure 1F ). These results suggest that in the db/db model the diabetic profile promotes a decrease of cardiac ACE2 that is restored under RAAS blockade. In db/db diabetic mice, the decrease of cardiac ACE2 seems to happen over time as younger animals (8 week-old) do not show decreased ACE2 activity in the heart (Ye et al., 2004) . Cardiac ACE2 is also decreased in streptozotocin induced-J o u r n a l P r e -p r o o f diabetic rats (Qiao et al., 2015; Shin et al., 2017) although other diabetic mouse models show rise of heart ACE2 when compared to their non-diabetic littermates Roca-Ho et al., 2017) . Even so, in vitro experiments suggest that that glucose can directly downregulate ACE2 in cardiac vascular smooth muscle cells (Lavrentyev and Malik, 2009) . ACE2 modulation in the heart as well as the effect of the RAAS blockade has been mostly studied in myocardial infarction (MI) both in rat models and in human. In a MI rat model, Ocaranza and collaborators showed that heart ACE2 activity was decreased in MI and the RAAS blockade with enalapril reversed it (Ocaranza et al., 2006) , similarly to what happens in our study. However, other studies performed in similar MI rat models have not reached the same conclusions (Burrell et al., 2005; Ishiyama et al., 2004) . In humans, ACE2 seems to be increased in the heart after MI (Burrell et al., 2005) and in idiopathic and ischemic cardiomyopathy (Goulter et al., 2004) . To our knowledge, the effect of RAAS blockade on cardiac ACE2 expression has not been studied in human.

Finally, we analyzed ACE2 activity in serum. ACE2 can be found both in cell membranes of the tissue cells and soluble (sACE2); which origins from shedding of the membrane bound ACE2 by the ADAM metallopeptidase domain 17 (ADAM17) (Lambert et al., 2005) . ACE2 only works as a receptor for SARS-CoV-2 at the organ level but it has been suggested that sACE2 could diminish the infection capacity of the virus by acting as a decoy Monteil et al., 2020; Wysocki et al., 2021) , although the low sACE2 blood levels would hardly produce this beneficial effect. Even so, it is interesting to know if serum ACE2 levels are modulated (or not) in diabetes or by RAAS blockers as it could be a signal of variations in tissue ACE2. In this sense, it has been postulated that ADAM17 could play an important counteracting role by competing for ACE2 cleavage with the serine-protease Transmembrane Serine Protease 2 (TMPRSS2), a fundamental protease for SARS-CoV-2 internalization (Palau et al., 2020) . We found that serum ACE2 was increased in the db/db when compared to the db/m and ramipril did not revert this effect ( Figure 3 ). Other studies have also described rise of blood ACE2 in diabetic mouse models (Riera et al., 2016; Roca-Ho et al., 2017; Wysocki et al., 2013) J o u r n a l P r e -p r o o f D ue to the a bove m e ntione d discre pa ncie s re ga rding AC E 2 m odula tion a m ong diffe re nt dia be tic a nim a l m ode ls a nd in hum a ns it is difficult to obta in a de finitive a nswe r for the que stion: "D oe s the R AAS blocka de induce ove re xpre ssion of AC E 2 ?". In a n ove ra ll ove rvie w, a tte nding to our da ta , a nd to e vide nce from othe r a uthors, the im pre ssion is tha t the dia be tic conte xt in m ost ca se s m odifie s AC E 2 e xpre ssion both in kidne y a nd in he a rt (down-or upre gula te s, de pe nding on the m ode l or spe cie ) a nd, tha t R AAS blocka de : (1 ) de cre a se s or doe s not m odify kidne y AC E 2 (both in e xpe rim e nta l m ode ls a nd in hum a n), be ne ficia l to re solve the vira l infe ction. M ore ove r, the infla m m a tory conte xt such a s the cytokine storm tha t ha ppe ns in a subse t of C O V ID -1 9 pa tie nts (M e hta e t a l., 2 0 2 0 ) ca n a lso re gula te AC E 2 e xpre ssion a lthough it is uncle a r in which dire ction (de La ng e t a l., 2 0 0 6 ; W u e t a l., 2 0 2 0 ). In a ny ca se , both upre gula tion a nd downre gula tion of AC E 2 could pote ntia lly be de trim e nta l during S AR S -C oV -2 infe ction sugge sting tha t AC E 2 le ve ls should be in a n e quilibrium ra nge (S outh e t a l., 2 0 2 0 ).

In conclusion, he re we de m onstra te in a dia be tic m ice m ode l tha t AC E inhibition only produce s AC E 2 upre gula tion in the dia be tic he a rt, whe re AC E 2 is de cre a se d se conda ry to dia be te s. T his doe s not ha ppe n in the kidne y or in the lung re inforcing the ide a tha t in m ost tissue s the R AAS blocka de doe s not incre a se AC E 2 e xpre ssion le ve ls.

E ve n the re sults we obta ine d in the he a rt, it is discussa ble whe the r the tre a tm e nt with AR B

or AC E i confe rs a re a l risk for incre a se d C O V ID -1 9 infe ction a nd worse ne d its prognosis.

R AAS blocka de ha s cle a r ca rdiova scula r be ne fits (F e g a n e t a l., 2 0 0 0 ; R o m e ro e t a l., 2 0 1 5 ), while it is unlike ly tha t low le ve ls of AC E 2 a re be ne ficia l for C O V ID -1 9 re solution.

J o u r n a l P r e -p r o o f

Severe COVID-19. Diabetes db200765

Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy?

Angiotensin-converting enzyme 2: Enhancing the degradation of angiotensin II as a potential therapy for diabetic nephropathy

Combination renin-angiotensin system blockade and angiotensin-converting enzyme 2 in experimental myocardial infarction: Implications for future therapeutic directions

Myocardial infarction increases ACE2 expression in rat and humans

Interferon-γ and interleukin-4 downregulate expression of the SARS coronavirus receptor ACE2 in Vero E6 cells

Antihypertensive medication uses and serum ACE2 levels: ACEIs/ARBs treatment does not raise serum levels of ACE2

Prevalence and impact of

ACE2 gene expression is upregulated in the human failing heart

Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Hypertension in diabetes study (HDS): I. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications

Upregulation of Angiotensin-Converting Enzyme 2 After Myocardial Infarction by Blockade of Angiotensin II Receptors

Angiotensin-converting enzyme 2 in lung diseases

7) formation in rat VSMCs

Renal ACE2 expression in human kidney disease

Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus

HLH Across Speciality Collaboration, UK, 2020. COVID-19: consider cytokine storm syndromes and immunosuppression

SARS-CoV-2 receptor ACE2 gene expression and RAAS inhibitors

Expression of ACE and ACE2 in Individuals With Diabetic Kidney Disease and Healthy Controls

Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2

SARS-CoV-2 Infections and ACE2: Clinical Outcomes Linked With Increased Morbidity and Mortality in Individuals With Diabetes

Enalapril attenuates downregulation of Angiotensin-converting enzyme 2 in the late phase of ventricular dysfunction in myocardial infarcted rat

SARS-coronavirus modulation of myocardial ACE2 expression and J o u r n a l P r e -p r o o f inflammation in patients with SARS

Human recombinant ACE2 reduces the progression of diabetic nephropathy

ADAM17 inhibition may exert a protective effect on COVID-19

Loss of angiotensin-converting enzyme-2 exacerbates diabetic cardiovascular complications and leads to systolic and vascular dysfunction: A critical role of the angiotensin II/AT1 receptor axis

Ibuprofen attenuates cardiac fibrosis in streptozotocin-induced diabetic rats

Decreased glomerular and tubular expression of ACE2 in patients with type 2 diabetes and kidney disease

Paricalcitol modulates ACE2 shedding and renal ADAM17 in NOD mice beyond proteinuria

Characterization of ACE and ACE2 expression within different organs of the NOD mouse

Novel RAAS agonists and antagonists: Clinical applications and controversies

Ang II (Angiotensin II) Conversion to Angiotensin-(1-7) in the Circulation Is POP (Prolyloligopeptidase)-Dependent and ACE2 (Angiotensin-Converting Enzyme 2)-Independent. Hypertens

The effect of fluvastatin on cardiac fibrosis and angiotensin-converting enzyme-2 expression in glucose-controlled diabetic rat hearts

Localization of ACE2 in the renal vasculature: Amplification by angiotensin II type 1 receptor blockade using telmisartan

Circulating ACE2 activity is increased in patients with type 1 diabetes and vascular complications

Controversies of renin-angiotensin system inhibition during the COVID-19 pandemic

Sound Science before Quick Judgement Regarding RAS Blockade in COVID-19

Good or bad: Application of RAAS inhibitors in COVID-19 patients with cardiovascular comorbidities

OpenSAFELY: factors associated with COVID-19 death in 17 million patients

Advances in research on ACE2 as a receptor for 2019-nCoV

Regulation of urinary ACE2 in diabetic mice

Kidney and Lung ACE2 Expression after an ACE Inhibitor or an Ang II Receptor Blocker: Implications for COVID-19

A Novel Soluble ACE2 Variant with Prolonged Duration of Action Neutralizes SARS-CoV-2 Infection in Human Kidney Organoids

ACE and ACE2 activity in diabetic mice

ACE2) mediates influenza H7N9 virus-induced acute lung injury

Increased ACE 2 and Decreased ACE Protein in Renal Tubules from Diabetic Mice: A Renoprotective Combination?

Glomerular localization and expression of Angiotensin-converting enzyme 2 and Angiotensinconverting enzyme: implications for albuminuria in diabetes

ACE2 exhibits protective effects against LPS-induced acute lung injury in mice by inhibiting the LPS-TLR4 pathway

Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction

SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues

lung (B) and heart (C) of the db/m, db/db and db/db treated with ramipril mice. -Supplemental Figure S2. ACE2 activity expressed in RFU/mg/h in membraneenriched extracts of kidney (A), lung (B) and heart (C) of the db/m